ClinicalTrials.gg
Not yet recruitingNCT07876128Updated Oct 15, 2026

A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)

A Phase 1/2 interventional study of MK-2750 and 5-HT3 serotonin receptor antagonist in Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells.

The goals of this trial are to learn:

  • About the safety of MK-2750 and if participants tolerate it. Tolerate means participants will receive trial treatment in the trial unless they need to stop it due to health problems.
  • How many participants have cancer respond (get smaller or go away) to MK-2750
02

Conditions studied

  • Advanced Solid Tumors
  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed advanced or squamous or nonsquamous non-small cell lung cancer (NSCLC); advanced or metastatic NSCLC; or advanced, unresectable, or metastatic pancreatic ductal adenocarcinoma (PDAC)
  • Has histologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma or squamous cell carcinoma of the esophagus; advanced or metastatic adenocarcinoma of the esophagus, gastroesophageal junction (GEJ), or gastric/stomach that is considered incurable by local therapies; or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies
  • Has provided sample or newly obtained biopsy of a tumor lesion not previously irradiated
  • If (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART)
  • If surface antigen (HBsAg)-positive, has received HBV antiviral therapy for at least 4 weeks and has undetectable hepatitis B virus (HBV) viral load
  • If history of virus (HCV) infection, has undetectable HCV viral load
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Is -infected with history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to allocation/randomization
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Has known additional that is progressing or has required active treatment within the past 2 years
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids; current diagnosis of ILD; or clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • Has active infection requiring systemic therapy other than those permitted in the protocol
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has uncontrolled significant cardiovascular disease or cerebrovascular disease, including Class III or IV congestive heart failure, unstable angina, uncontrolled symptomatic arrhythmia, prolongation of interval by Fridericia (QTcF) to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose Comparison Cohort

    Participants will receive MK-2750

    Biological: MK-2750 · Drug: 5-HT3 serotonin receptor antagonist · Drug: NK-1 receptor antagonist · Drug: Corticosteroid · Drug: Steroid mouthwash (dexamethasone or equivalent)

  • Experimental
    Part 2: Signal-Finding Cohorts

    Participants will receive MK-2750

    Biological: MK-2750 · Drug: 5-HT3 serotonin receptor antagonist · Drug: NK-1 receptor antagonist · Drug: Corticosteroid · Drug: Steroid mouthwash (dexamethasone or equivalent)

Interventions

  • BiologicalMK-2750

    Administered as an intravenous (IV) infusion

  • Drug5-HT3 serotonin receptor antagonist

    Administered as a premedication per the approved product label

  • DrugNK-1 receptor antagonist

    Administered as a premedication per the approved product label

  • DrugCorticosteroid

    Administered as a premedication per the approved product label

  • Administered orally per the approved product label as a rescue medication

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 2 years

  2. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 2 years

  3. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by investigator will be presented.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by investigator, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  2. Maximum Plasma Concentration (Cmax) of MK-2750 Free Payload

    Blood samples will be collected to determine Cmax of MK-2750 Free Payload.

    Time frame: Predose and at designated time points up to approximately 2 years

  3. Cmax of MK-2750 Total Antibodies (TAb)

    Blood samples will be collected to determine Cmax of MK-2750 Total Antibodies.

    Time frame: Predose and at designated time points up to approximately 2 years

  4. Cmax of MK-2750 Antibody-Drug Conjugate (ADC)

    Blood samples will be collected to determine Cmax of MK-2750 Antibody-Drug Conjugate.

    Time frame: Predose and at designated time points up to approximately 2 years

  5. Trough Concentration (Ctrough) of MK-2750 Free Payload

    Blood samples will be collected to determine Ctrough of MK-2750 Free Payload.

    Time frame: Predose and at designated time points up to approximately 2 years

  6. Ctrough of MK-2750 TAb

    Blood samples will be collected to determine Ctrough of MK-2750 Total Antibodies.

    Time frame: Predose and at designated time points up to approximately 2 years

  7. Ctrough of MK-2750 ADC

    Blood samples will be collected to determine Ctrough of MK-2750 Antibody-Drug Conjugate.

    Time frame: Predose and at designated time points up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2029, 28 months later.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 28 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 12, 2029
CompletionEst.
May 30, 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876128
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 12, 2029 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion